Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis

T Bauer, HJ Bouman, JW van Werkum, NF Ford… - Bmj, 2011 - bmj.com
Objective To evaluate the accumulated information from genetic association studies
investigating the impact of variants of the cytochrome P450 (CYP) 2C19 genotype on the clinical …

The metabolism of clopidogrel: CYP2C19 is a minor pathway

NF Ford - The Journal of Clinical Pharmacology, 2016 - Wiley Online Library
The major metabolic pathway of clopidogrel is conversion to carboxylic acid by an esterase (CES1),
forming clopidogrelic acid (SR26334) that is inactive. There is agreement on the …

Clopidogrel resistance: pharmacokinetic or pharmacogenetic?

NF Ford - The Journal of Clinical Pharmacology, 2009 - Wiley Online Library
Clopidogrel is important for the management of acute coronary syndromes and, along with
aspirin, is recommended in the American College of Cardiology/American Heart Association …

Imidazo [1, 5-a] pyridines: a new class of thromboxane A2 synthetase inhibitors

NF Ford, LJ Browne, T Campbell… - Journal of medicinal …, 1985 - ACS Publications
Thromboxane A2 (TxA2) is an extremely unstable natural product with potent vasoconstricting,
bronchocon-stricting, and platelet aggregating activities. 2 It has been implicated in the …

Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and …

…, B Pitt, DA Berry, SM Berry, NF Ford… - Archives of internal …, 2004 - jamanetwork.com
Background In randomized trials of secondary prevention, pravastatin sodium and aspirin
reduce risks of cardiovascular disease. Pravastatin has a predominantly delayed …

Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects

MR Marino, K Langenbacher, NF Ford… - The Journal of …, 1998 - Wiley Online Library
The safety, pharmacokinetics, and pharmacodynamics of single and multiple doses of the
angiotensin II (AII) AT 1 blocker irbesartan were assessed in healthy subjects. In this single‐…

Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency

DA Sica, RE Cutler, RJ Parmer, NF Ford - Clinical pharmacokinetics, 1991 - Springer
The phosphinyl ester prodrug fosinopril, a new angiotensin converting enzyme (ACE)
inhibitor, is fully hydrolysed after oral administration to the pharmacologically active diacid, …

The pharmacokinetics of irbesartan in hypertensive children and adolescents

…, OW Hadjilambris, P Slugg, NF Ford… - The Journal of …, 2001 - Wiley Online Library
An open‐label study was conducted to characterize the pharmacokinetics and antihypertensive
response to irbesartan in children (1–12 years) and adolescents (13–16 years) with …

Measurement of 2, 4-toluenediamine in urine and serum samples from women with Meme or Replicon breast implants

RT Hester Jr, NF Ford, JP Gale… - Plastic and …, 1997 - journals.lww.com
The objective of this matched case-control study was to determine whether women with
Même or Replicon polyurethane-covered silicone breast implants are exposed to clinically …

Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis

…, RH Raymond, NF Ford… - The Journal of …, 1998 - Wiley Online Library
The effect of hepatic impairment on the clinical pharmacology of the angiotensin II (AII)
receptor antagonist irbesartan was assessed by comparing pharmacokinetic and …